MAPT (P10636) variants and mutations
MAPT (also known as P10636) is a human protein-coding gene encoding a microtubule-associated protein tau protein. Its tau isoforms stabilize and organize neuronal microtubules, especially in axons, while also participating in transport and signaling. Pathogenic variants cause inherited frontotemporal dementia, and abnormal tau aggregation defines multiple neurodegenerative tauopathies. This analysis covers 1,101 MAPT variants and mutations. Of these, 39% have computational variant effect predictions. Disease context includes frontotemporal dementia, Pick disease, and supranuclear palsy, progressive, 1. Example MAPT variants include A2S, E3E, and P4L.
Variant analysis overview
- Gene: MAPT
- Protein: P10636
- UniProt accession: P10636
- Organism: Homo sapiens
- Variants analyzed: 1101
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 953 unspecified-consequence records; 55 synonymous variants; 3 in-frame deletions; 72 missense variants; 2 stop-gained variants; 7 frameshift variants; 2 splice-region variants; 7 substitution
- Prediction scores: 425 variants have prediction scores (39% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: frontotemporal dementia, Pick disease, supranuclear palsy, progressive, 1, Progressive supranuclear palsy - parkinsonism, Atypical progressive supranuclear palsy, Classical progressive supranuclear palsy, progressive supranuclear palsy-parkinsonism syndrome, late-onset Parkinson disease, semantic dementia, progressive supranuclear palsy, Parkinson disease, Hereditary late-onset Parkinson disease.
Protein structure and variant hotspots
- Protein features: 80 post-translational modification sites.
- PTM context: 63 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable MAPT variants
Examples include A2S, E3E, P4L, P4S, P4T, P4P, R5C, R5H. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2S (p.Ala2Ser), rs2509439219, ClinGen CA399898425, ClinVar RCV002620679, Uncertain significance, Frontotemporal dementia
- E3E (p.Glu3Glu), gnomAD 17-45962346-G-A, CADD 5.63
- P4L (p.Pro4Leu), gnomAD rs1477365646, cosmic curated COSV10510, REVEL 0.13, MetaLR 0.22
- P4S (p.Pro4Ser), cosmic curated COSV52238
- P4T (p.Pro4Thr), rs974837695, ClinGen CA291105330, ClinVar RCV002049876, ClinVar RCV002506868, REVEL 0.11, MetaLR 0.22, Uncertain significance, Frontotemporal dementia; Parkinson disease, late-onset; Progressive supranuclear
- P4P (p.Pro4Pro), gnomAD 17-45962349-C-A, CADD 1.92
- R5C (p.Arg5Cys), rs766166210, ClinGen CA8617493, NCI-TCGA Cosmic COSV9929, ClinVar RCV001123790, REVEL 0.19, MetaLR 0.21, Conflicting interpretations, MAPT-Related Spectrum Disorders; Frontotemporal dementia
- R5H (p.Arg5His), rs63750959, ClinGen CA257191, ClinVar RCV000015330, ClinVar RCV004700240, REVEL 0.19, MetaLR 0.19, Conflicting interpretations, not provided; Frontotemporal dementia
- R5L (p.Arg5Leu), rs63750959, ClinGen CA225379, ClinVar RCV000084498, ClinVar RCV002508758, REVEL 0.26, MetaLR 0.19, Pathogenic, Supranuclear palsy, progressive, 1
- R5S (p.Arg5Ser), cosmic curated COSV99290
- Q6* (p.Gln6Ter), gnomAD rs2070528503, CADD 35.00
- Q6Q (p.Gln6Gln), rs769584478, gnomAD 17-45962355-G-A, CADD 4.94
- E7* (p.Glu7Ter), ExAC rs774795793, gnomAD rs774795793, CADD 36.00
- E7G (p.Glu7Gly), cosmic curated COSV52240
- E7V (p.Glu7Val), cosmic curated COSV10805
- E7del (p.Glu7del), gnomAD 17-45962353-CAGG-, CADD 15.60
- E7E (p.Glu7Glu), gnomAD 17-45962358-G-A, CADD 1.06
- F8S (p.Phe8Ser), NCI-TCGA Cosmic COSV9929, cosmic curated COSV99291, Variant assessed as somatic; moderate impact.
- F8Y (p.Phe8Tyr), TOPMed rs1276637062, gnomAD rs1276637062, REVEL 0.10, MetaLR 0.13
- F8C (p.Phe8Cys), gnomAD 17-45962360-T-G, REVEL 0.12, MetaLR 0.17
- F8F (p.Phe8Phe), rs886700939, gnomAD 17-45962361-C-T, CADD 2.91
- F8L (p.Phe8Leu), gnomAD 17-45962361-C-A, REVEL 0.12, MetaLR 0.13
- E9K (p.Glu9Lys), rs762595428, ClinGen CA8617496, ClinVar RCV001815827, ClinVar RCV001869641, REVEL 0.03, MetaLR 0.04, Uncertain significance, not provided; Frontotemporal dementia
- E9Q (p.Glu9Gln), gnomAD 17-45962362-G-C, REVEL 0.07, MetaLR 0.04
- V10A (p.Val10Ala), Ensembl rs2070531278
- V10M (p.Val10Met), TOPMed rs1204505552, gnomAD rs1204505552, REVEL 0.03, MetaLR 0.07
- V10E (p.Val10Glu), gnomAD 17-45962366-T-A, REVEL 0.03, MetaLR 0.09
- M11I (p.Met11Ile), cosmic curated COSV10457, gnomAD rs1440753861, REVEL 0.02, MetaLR 0.08
- M11L (p.Met11Leu), rs1262800598, ClinGen CA399898481, ClinVar RCV002982990, TOPMed rs1262800598, REVEL 0.02, MetaLR 0.05, Uncertain significance, Frontotemporal dementia
- M11V (p.Met11Val), gnomAD 17-45962368-A-G, REVEL 0.03, MetaLR 0.05
- E12* (p.Glu12Ter), TOPMed rs2070532470
- E12E (p.Glu12Glu), rs375852870, gnomAD 17-45962373-A-G, CADD 4.14
- D13N (p.Asp13Asn), rs773820376, NCI-TCGA Cosmic COSV5223, cosmic curated COSV52238, ExAC rs773820376, AlphaMissense 0.20, MetaLR 0.21, Variant assessed as somatic; moderate impact.
- D13D (p.Asp13Asp), rs760999100, gnomAD 17-45962376-T-C, CADD 2.82
- H14D (p.His14Asp), TOPMed rs2070534028
- H14Y (p.His14Tyr), NCI-TCGA Cosmic COSV5223, cosmic curated COSV52238, Variant assessed as somatic; moderate impact.
- H14R (p.His14Arg), gnomAD 17-45962378-A-G, REVEL 0.03, MetaLR 0.09
- H14H (p.His14His), rs759306195, gnomAD 17-45962379-C-T, CADD 0.06
- A15S (p.Ala15Ser), rs143210139, ESP rs143210139, ExAC rs143210139, gnomAD rs143210139, REVEL 0.13, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- A15T (p.Ala15Thr), cosmic curated COSV52240, ESP rs143210139, ExAC rs143210139, gnomAD rs143210139, REVEL 0.09, MetaLR 0.05
- G16R (p.Gly16Arg), TOPMed rs1474279652
- G16V (p.Gly16Val), rs755131800, ClinGen CA8617502, ClinVar RCV000662117, ClinVar RCV000662118, REVEL 0.06, MetaLR 0.20, Uncertain significance, Frontotemporal dementia; Progressive supranuclear ophthalmoplegia; Pick disease
- T17M (p.Thr17Met), rs144611688, ClinGen CA8617504, ClinVar RCV000874605, ClinVar RCV002064770, REVEL 0.10, MetaLR 0.10, Benign/Likely benign, Frontotemporal dementia; not specified; not provided
- T17S (p.Thr17Ser), ExAC rs765496574, gnomAD rs765496574, REVEL 0.03, MetaLR 0.05
- T17A (p.Thr17Ala), gnomAD 17-45962386-A-G, REVEL 0.01, MetaLR 0.06
- T17T (p.Thr17Thr), rs369969350, gnomAD 17-45962388-G-A, CADD 0.87
- Y18* (p.Tyr18Ter), gnomAD 17-45962391-C-G, CADD 26.80
- Y18Y (p.Tyr18Tyr), rs63750811, gnomAD 17-45962391-C-T, CADD 0.56
- G19E (p.Gly19Glu), TOPMed rs1568240688, gnomAD rs1568240688, REVEL 0.02, MetaLR 0.08
- G19R (p.Gly19Arg), rs746904464, ExAC rs746904464, TOPMed rs746904464, gnomAD rs746904464, REVEL 0.06, MetaLR 0.09, Uncertain significance, Inborn genetic diseases
- G19W (p.Gly19Trp), gnomAD 17-45962392-G-T, REVEL 0.10, MetaLR 0.10
- G19G (p.Gly19Gly), gnomAD 17-45962394-G-A, CADD 4.47
- L20F (p.Leu20Phe), rs1430583458, ClinGen CA399898568, ClinVar RCV001874485, TOPMed rs1430583458, REVEL 0.13, MetaLR 0.09, Uncertain significance, Frontotemporal dementia
- L20L (p.Leu20Leu), rs757284182, gnomAD 17-45962395-T-C, CADD 1.29
- G21E (p.Gly21Glu), ExAC rs781076528, TOPMed rs781076528, gnomAD rs781076528, REVEL 0.03, MetaLR 0.03, Uncertain significance
- G21V (p.Gly21Val), rs781076528, ClinGen CA8617508, ClinVar RCV000821910, ClinVar RCV004029086, REVEL 0.14, MetaLR 0.06, Uncertain significance, Frontotemporal dementia; Inborn genetic diseases
- G21W (p.Gly21Trp), NCI-TCGA Cosmic COSV5224, cosmic curated COSV52249, Variant assessed as somatic; moderate impact.
- G21G (p.Gly21Gly), rs200084740, gnomAD 17-45962400-G-A, CADD 8.30
- D22E (p.Asp22Glu), Ensembl rs2145309097
- D22N (p.Asp22Asn), ExAC rs745662662, gnomAD rs745662662
- D22G (p.Asp22Gly), gnomAD 17-45962396-T-TG, CADD 23.00
- R23K (p.Arg23Lys), cosmic curated COSV52248, gnomAD rs1224565965, REVEL 0.13, MetaLR 0.05
- R23S (p.Arg23Ser), rs193920967, NCI-TCGA Cosmic COSV5224, NCI-TCGA Cosmic COSV9929, cosmic curated COSV99291, AlphaMissense 0.34, MetaLR 0.08, Uncertain significance, Prostate cancer
- R23G (p.Arg23Gly), gnomAD 17-45962404-A-G, REVEL 0.22, MetaLR 0.09
- K24R (p.Lys24Arg), gnomAD 17-45962408-A-G, REVEL 0.10, MetaLR 0.07
- K24K (p.Lys24Lys), rs2070542553, gnomAD 17-45962409-A-G, CADD 6.53
- D25H (p.Asp25His), cosmic curated COSV10941
- D25N (p.Asp25Asn), gnomAD 17-45962410-G-A, REVEL 0.04, MetaLR 0.09
- D25Y (p.Asp25Tyr), gnomAD 17-45962410-G-T, REVEL 0.14, MetaLR 0.09
- Q26H (p.Gln26His), Ensembl rs2070542971
- Q26L (p.Gln26Leu), cosmic curated COSV52240
- G27E (p.Gly27Glu), rs769331823, ClinGen CA8617510, ClinVar RCV001921514, ClinVar RCV002560453, REVEL 0.04, MetaLR 0.07, Conflicting interpretations, Inborn genetic diseases; Frontotemporal dementia; not specified
- G27R (p.Gly27Arg), TOPMed rs1290341065, gnomAD rs1290341065, REVEL 0.14, MetaLR 0.13
- G27W (p.Gly27Trp), gnomAD 17-45962416-G-T, REVEL 0.12, MetaLR 0.15
- G28S (p.Gly28Ser), 1000Genomes rs186536533, ExAC rs186536533, gnomAD rs186536533, REVEL 0.04, MetaLR 0.06
- G28V (p.Gly28Val), Ensembl rs1598169163
- G28D (p.Gly28Asp), gnomAD 17-45962420-G-A, REVEL 0.04, MetaLR 0.05
- G28G (p.Gly28Gly), rs2145309593, gnomAD 17-45962421-C-T, CADD 7.75
- Y29Y (p.Tyr29Tyr), rs1225695055, gnomAD 17-45962424-C-T, CADD 4.28
- T30A (p.Thr30Ala), rs748728879, UniProt VAR 064623, ExAC rs748728879, TOPMed rs748728879, REVEL 0.02, MetaLR 0.05
- T30I (p.Thr30Ile), rs374996228, ClinGen CA8617513, ClinVar RCV001229146, ClinVar RCV002491726, REVEL 0.11, MetaLR 0.15, Uncertain significance, Frontotemporal dementia; Supranuclear palsy, progressive, 1; Pick disease
- T30K (p.Thr30Lys), rs2509443882, ClinGen CA2580094031, ClinVar RCV002304743, Uncertain significance, Frontotemporal dementia
- T30N (p.Thr30Asn), cosmic curated COSV10727
- T30S (p.Thr30Ser), cosmic curated COSV52246, ESP rs374996228, ExAC rs374996228, TOPMed rs374996228, Uncertain significance
- M31I (p.Met31Ile), gnomAD rs1214314857, REVEL 0.02, MetaLR 0.04
- M31L (p.Met31Leu), TOPMed rs1408013394, gnomAD rs1408013394, REVEL 0.02, MetaLR 0.02
- H32Y (p.His32Tyr), gnomAD 17-45962431-C-T, REVEL 0.06, MetaLR 0.05
- D34Y (p.Asp34Tyr), rs193920968, ClinGen CA174627, cosmic curated COSV52244, ClinVar RCV000149239, REVEL 0.21, MetaLR 0.21, Uncertain significance, Prostate cancer
- D34N (p.Asp34Asn), gnomAD 17-45962437-G-A, REVEL 0.10, MetaLR 0.20
- Q35Q (p.Gln35Gln), gnomAD 17-45962442-A-G, CADD 0.40
- E36D (p.Glu36Asp), cosmic curated COSV52237, ExAC rs773762393, gnomAD rs773762393, REVEL 0.07, MetaLR 0.06
- E36E (p.Glu36Glu), rs773762393, gnomAD 17-45962445-G-A, CADD 2.71
- G37A (p.Gly37Ala), TOPMed rs966689443, gnomAD rs966689443, REVEL 0.04, MetaLR 0.17, Uncertain significance
- G37S (p.Gly37Ser), ESP rs146476223, TOPMed rs146476223, gnomAD rs146476223, REVEL 0.10, MetaLR 0.18
- G37V (p.Gly37Val), rs966689443, ClinGen CA399898799, ClinVar RCV001756236, TOPMed rs966689443, REVEL 0.12, MetaLR 0.20, Uncertain significance, not provided
- G37C (p.Gly37Cys), gnomAD 17-45962446-G-T, REVEL 0.09, MetaLR 0.22
- D38G (p.Asp38Gly), gnomAD rs1198505498, REVEL 0.19, MetaLR 0.15
- D38D (p.Asp38Asp), gnomAD 17-45962451-C-T, CADD 4.88
- T39M (p.Thr39Met), ExAC rs372017279, TOPMed rs372017279, gnomAD rs372017279, REVEL 0.02, MetaLR 0.03
- T39T (p.Thr39Thr), rs63750529, gnomAD 17-45962454-G-A, CADD 1.34
- D40D (p.Asp40Asp), rs191362093, gnomAD 17-45962457-C-T, CADD 2.45
- A41T (p.Ala41Thr), rs115239819, ClinGen CA8617517, ClinVar RCV001953160, 1000Genomes rs115239819, REVEL 0.04, MetaLR 0.03, Uncertain significance, Frontotemporal dementia
- G42C (p.Gly42Cys), NCI-TCGA Cosmic COSV9929, cosmic curated COSV99290, Variant assessed as somatic; moderate impact.
- G42D (p.Gly42Asp), cosmic curated COSV10510
- L43P (p.Leu43Pro), gnomAD 17-45962465-T-C, REVEL 0.17, MetaLR 0.14
- L43L (p.Leu43Leu), gnomAD 17-45962466-G-C, CADD 4.81
- E45* (p.Glu45Ter), cosmic curated COSV52244, CADD 50.00, SIFT 0.14
- E45D (p.Glu45Asp), gnomAD rs1317176100, REVEL 0.22, MetaLR 0.12
- E45K (p.Glu45Lys), cosmic curated COSV10727, REVEL 0.10, MetaLR 0.14
- E45V (p.Glu45Val), rs764226855, ClinGen CA8617538, ClinVar RCV003515490, ExAC rs764226855, REVEL 0.15, MetaLR 0.12, Uncertain significance, Frontotemporal dementia
- S46S (p.Ser46Ser), gnomAD 17-45971863-T-A, CADD 9.12
- P47L (p.Pro47Leu), NCI-TCGA Cosmic COSV9929, cosmic curated COSV99290, REVEL 0.19, MetaLR 0.16, Variant assessed as somatic; moderate impact.
- P47S (p.Pro47Ser), rs751685945, NCI-TCGA Cosmic COSV5223, cosmic curated COSV52236, ExAC rs751685945, REVEL 0.12, MetaLR 0.12, Variant assessed as somatic; moderate impact.
- L48V (p.Leu48Val), ExAC rs762046989, TOPMed rs762046989, gnomAD rs762046989, REVEL 0.14, MetaLR 0.12
- L48P (p.Leu48Pro), gnomAD 17-45971868-T-C, REVEL 0.03, MetaLR 0.03
- Q49P (p.Gln49Pro), gnomAD 17-45971871-A-C, REVEL 0.17, MetaLR 0.14
- T50A (p.Thr50Ala), Ensembl rs2071713435
- T50S (p.Thr50Ser), Ensembl rs2071713435
- T50I (p.Thr50Ile), gnomAD 17-45971874-C-T, REVEL 0.01, MetaLR 0.06
- T50T (p.Thr50Thr), rs2071713913, gnomAD 17-45971875-C-T, CADD 7.06
- P51P (p.Pro51Pro), rs1263653688, gnomAD 17-45971878-C-A, CADD 0.15
- T52A (p.Thr52Ala), ExAC rs767543900, TOPMed rs767543900, gnomAD rs767543900
- T52I (p.Thr52Ile), NCI-TCGA Cosmic COSV5224, cosmic curated COSV52248, REVEL 0.04, MetaLR 0.04, Variant assessed as somatic; moderate impact.
- T52P (p.Thr52Pro), ExAC rs767543900, TOPMed rs767543900, gnomAD rs767543900
- T52L (p.Thr52Leu), gnomAD 17-45971873-AC-A, CADD 23.30
- E53D (p.Glu53Asp), rs1196222070, ClinGen CA399898082, ClinVar RCV003844613, TOPMed rs1196222070, REVEL 0.03, MetaLR 0.02, Uncertain significance, Frontotemporal dementia
- E53A (p.Glu53Ala), gnomAD 17-45971883-A-C, REVEL 0.04, MetaLR 0.06
- D54E (p.Asp54Glu), NCI-TCGA Cosmic COSV9929, cosmic curated COSV99291, Variant assessed as somatic; moderate impact.
- D54D (p.Asp54Asp), rs750428288, gnomAD 17-45971887-C-T, CADD 0.81
- G55R (p.Gly55Arg), rs1012826460, NCI-TCGA Cosmic COSV9929, cosmic curated COSV99290, gnomAD rs1012826460, REVEL 0.15, MetaLR 0.24, Variant assessed as somatic; moderate impact.
- G55V (p.Gly55Val), TOPMed rs944187436
- E57E (p.Glu57Glu), gnomAD 17-45971896-G-A, CADD 11.80
- E58E (p.Glu58Glu), gnomAD 17-45971899-A-G, CADD 11.60
- P59L (p.Pro59Leu), rs143138715, ClinGen CA8617543, cosmic curated COSV99290, ClinVar RCV001521462, REVEL 0.07, MetaLR 0.05, Conflicting interpretations, not provided; Frontotemporal dementia
- P59T (p.Pro59Thr), NCI-TCGA Cosmic COSV5224, cosmic curated COSV52244, Variant assessed as somatic; moderate impact.
- P59S (p.Pro59Ser), gnomAD 17-45971900-C-T, REVEL 0.04, MetaLR 0.09
- P59P (p.Pro59Pro), rs370131551, gnomAD 17-45971902-G-A, CADD 2.30
- G60R (p.Gly60Arg), TOPMed rs2071717665
- G60S (p.Gly60Ser), NCI-TCGA Cosmic COSV9928, cosmic curated COSV99289, TOPMed rs2071717665, Variant assessed as somatic; moderate impact.
- G60V (p.Gly60Val), 1000Genomes rs552538809, ExAC rs552538809, gnomAD rs552538809, REVEL 0.07, MetaLR 0.13, Uncertain significance, Frontotemporal dementia; not specified
- G60G (p.Gly60Gly), rs1187428547, gnomAD 17-45971905-C-T, CADD 12.70
- E62K (p.Glu62Lys), cosmic curated COSV52248
- E62V (p.Glu62Val), Ensembl rs2071719114
- T63A (p.Thr63Ala), gnomAD 17-45971912-A-G, REVEL 0.07, MetaLR 0.05
- T63T (p.Thr63Thr), gnomAD 17-45971914-C-T, CADD 11.50
- S64C (p.Ser64Cys), gnomAD rs1002674939, REVEL 0.16, MetaLR 0.17
- A66S (p.Ala66Ser), NCI-TCGA Cosmic COSV5224, cosmic curated COSV52244, Variant assessed as somatic; moderate impact.
- A66A (p.Ala66Ala), rs2145467235, gnomAD 17-45971923-T-C, CADD 14.70
- K67R (p.Lys67Arg), ExAC rs754588669, TOPMed rs754588669, REVEL 0.09, MetaLR 0.06
- K67N (p.Lys67Asn), gnomAD 17-45971926-G-C, REVEL 0.14, MetaLR 0.08
- S68N (p.Ser68Asn), TOPMed rs1447868249, gnomAD rs1447868249, REVEL 0.19, MetaLR 0.19
- S68T (p.Ser68Thr), TOPMed rs1447868249, gnomAD rs1447868249, REVEL 0.20, MetaLR 0.19
- S68R (p.Ser68Arg), gnomAD 17-45978404-A-C, REVEL 0.05, MetaLR 0.05
- S68I (p.Ser68Ile), gnomAD 17-45978405-G-T, REVEL 0.03, MetaLR 0.04
- T69A (p.Thr69Ala), rs778599496, ClinGen CA8617547, ClinVar RCV003399478, ExAC rs778599496, REVEL 0.13, MetaLR 0.16, Uncertain significance, MAPT-related disorder
- T69I (p.Thr69Ile), gnomAD rs1168788082, REVEL 0.14, MetaLR 0.18
- T71R (p.Thr71Arg), ExAC rs747643127, gnomAD rs747643127, REVEL 0.20, MetaLR 0.15
- A72V (p.Ala72Val), rs771618879, NCI-TCGA Cosmic COSV9929, cosmic curated COSV99290, ExAC rs771618879, REVEL 0.08, MetaLR 0.05, Variant assessed as somatic; moderate impact.
- A72A (p.Ala72Ala), rs781640412, gnomAD 17-45971941-G-A, CADD 6.21
- A72T (p.Ala72Thr), gnomAD 17-45971945-G-A, REVEL 0.12, MetaLR 0.12
- A72G (p.Ala72Gly), rs886053030, gnomAD 17-45978375-C-G, REVEL 0.18, AlphaMissense 0.19
- E73K (p.Glu73Lys), gnomAD 17-45971942-G-A, REVEL 0.04, MetaLR 0.15
- E73A (p.Glu73Ala), rs745928592, gnomAD 17-45978378-A-C, REVEL 0.13, MetaLR 0.16
- E73E (p.Glu73Glu), gnomAD 17-45978379-A-G, CADD 10.40
- D74H (p.Asp74His), Ensembl rs2071723093
- D74G (p.Asp74Gly), rs2072082663, gnomAD 17-45974384-GAT-G, CADD 34.00
- D74A (p.Asp74Ala), gnomAD 17-45974385-A-C, REVEL 0.18, CADD 33.00
- D74E (p.Asp74Glu), gnomAD 17-45974385-ATGTG, CADD 31.00
- D74D (p.Asp74Asp), rs1193595831, gnomAD 17-45974386-T-C, CADD 13.80
- V75A (p.Val75Ala), ExAC rs774890160, gnomAD rs774890160, REVEL 0.06, CADD 12.60
- V75L (p.Val75Leu), Ensembl rs1568261957, REVEL 0.10, CADD 24.00
- V75M (p.Val75Met), Ensembl rs1568261957
- V75* (p.Val75Ter), rs1449428925, gnomAD 17-45974386-TG-T, CADD 25.30
- V75V (p.Val75Val), rs1330718698, gnomAD 17-45974389-G-A, CADD 12.30
- T76I (p.Thr76Ile), 1000Genomes rs578177484, ExAC rs578177484, gnomAD rs578177484, REVEL 0.13, CADD 29.20
- T76K (p.Thr76Lys), 1000Genomes rs578177484, ExAC rs578177484, gnomAD rs578177484, REVEL 0.13, CADD 25.60
- T76S (p.Thr76Ser), cosmic curated COSV10510, Ensembl rs2145508106, REVEL 0.13, CADD 26.20
- T76del (p.Thr76del), gnomAD 17-45974388-TGAC-, CADD 22.20
- T76R (p.Thr76Arg), gnomAD 17-45974391-C-G, REVEL 0.15, CADD 26.30
- T76P (p.Thr76Pro), gnomAD 17-45978398-A-C, REVEL 0.17, MetaLR 0.18
Public MAPT analysis runs
- MAPT analysis run — MAPT (1,101 variants) — completed 2026-08-10